Periodic Reporting for period 1 - PulseHaler (PulseHaler: Improving the Lives of COPD Patients)
Reporting period: 2017-12-01 to 2018-04-30
Respinova Ltd., has invented a device, called PulseHaler™, to treat COPD by opening the small airways which are known to collapse in COPD patients thereby making it increasingly difficult to breathe.
In a clinical trial, a prototype of the PulseHaler™ was shown to be safe and effective in substantially improving the functional capabilities of COPD sufferers.
In this Phase I grant project, Respinova conducted a feasibility study using market analysis, clinical and technical risk assessment, and customer acceptance validation. The company interviewed key opinion leaders to identify issues with introduction of the PulseHaler product, and conducted initial reimbursement assessments for key markets. The company also analysed key competitors, both direct and indirect, to identify potential risks and develop risk mitigations. Stakeholders and potential partners were identified, and issues with go to market strategy were identified.
We further developed our Technology and Innovation Roadmap by analyzing feedback from KOL’s regarding our planned product roadmap as well as use-case scenarios. We identified additional applications for our technology as well as features that can be added to current products to enhance functionality.